secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001005286-23-000108
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Biomedical Q4 revenue up 12% to $31.5M; net loss widens to $33.8M on debt refinancing
--------------------------------------------------------------------------------

- Q4 consolidated revenue $31.5M (+12.2% YoY); gross profit $8.4M (-33.9% YoY); net loss from continuing ops $33.8M vs $1.0M loss prior year.
- Full year FY2023 revenue $103.3M (-7.2% YoY); net loss from continuing ops $69.0M; adjusted EBITDA $5.8M vs $22.9M prior year.
- Q4 net loss includes $23.8M loss on debt refinancing and $6.8M restructuring/legal charges; adjusted EBITDA fell to $3.7M from $9.1M.
- CEO notes final divestitures of Curation Foods, expanded supply agreement with Alcon, and new customer projects added in Q4.
- Capacity expansions: multi-use fillers to double filling capacity to ~45M units; HA fermentation moving to 24/7 to boost capacity up to 50% by June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/0001005286-23-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/lndc-20230831.htm
  HTML page:      https://secwatch.observer/filing/0001005286-23-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer